DA-8010

06/01/2022 - "Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study."
06/01/2022 - "We evaluated the clinical efficacy and safety of DA-8010 in overactive bladder (OAB) patients. "
04/17/2020 - "DA-8010 is a novel compound developed for the treatment of overactive bladder (OAB) and urinary incontinence. "
01/15/2019 - "These findings suggest that DA-8010 is a potent muscarinic M3 receptor antagonist to be highly selective for bladder over salivary gland, which might be a promising agent with greater efficacy and less dry mouth in the treatment of overactive bladder."
04/17/2020 - "The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction."

04/17/2020 - "Study animals were divided into the following five groups of seven animals each: a sham-operated control group, a control group with partial bladder outlet obstruction (BOO) (OAB group), and three DA-8010 (doses of 0.3 mg/kg/day, 1 mg/kg/day, and 3 mg/kg/day, respectively) with partial BOO groups. "
04/17/2020 - "The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction."

06/01/2022 - "Adverse drug reactions (ADRs) were observed in 3.95% of placebo, 6.67% of DA-8010 2.5 mg, 18.42% of DA-8010 5 mg, and 17.33% of solifenacin 5 mg groups. "

04/17/2020 - "DA-8010 is a novel compound developed for the treatment of overactive bladder (OAB) and urinary incontinence. "